Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300383 | 0.85 | CSNK1E (0.54) | CSNK1EF2MAOAEPHX1BCHE | |
| SCHEMBL4688760 | 0.85 | CSNK1E (0.49) | CSNK1EF2MAOAEPHX1BCHE | |
| Hydrochloric Acid SCHEMBL7310009 | 0.84 | CSNK1E (0.53) | CSNK1EF2MAOAEPHX1BCHE | |
| SCHEMBL3355611 | 0.83 | CSNK1E (0.56) | CSNK1EF2MAOAEPHX1BCHE | |
| SCHEMBL4692426 | 0.82 | CSNK1E (0.50) | CSNK1EF2EPHX1BCHELAP3 | |
| SCHEMBL1286638 | 0.81 | CSNK1E (0.51) | CSNK1ECYP2D6F2MAOAEPHX1 | |
| SCHEMBL6895260 | 0.81 | CSNK1E (0.51) | CSNK1ECYP1A2CYP2D6F2MAOA | |
| Hydrochloric Acid SCHEMBL5218959 | 0.81 | CSNK1E (0.55) | CSNK1EF2MAOAEPHX1BCHE | |
| SCHEMBL1286637 | 0.81 | CSNK1E (0.51) | CSNK1ECYP2D6F2MAOAEPHX1 | |
| SCHEMBL1057036 | 0.81 | CSNK1E (0.51) | CSNK1ECYP2D6F2MAOAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2010107384-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-09-23 | — | — | WO | disclosed |
| US-7557137-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557137-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1692143-B1 | TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-15 | — | — | US | disclosed |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-15 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| WO-2006103088-A1 | NOVEL HYDROXYETHYLAMINE AND KETONE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| WO-2004013098-A1 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | CSNK1E 580/4885CYP1A2 792/4885CYP3A4 1874/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | CSNK1E 2024/4885CYP1A2 226/4885CYP3A4 1415/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | CSNK1E 1817/4885CYP1A2 823/4885CYP3A4 1901/4885 |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, APP, BACE2 | CSNK1E 209/4885CYP1A2 1356/4885CYP3A4 1372/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | CSNK1E 3282/4885CYP1A2 230/4885CYP3A4 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.